And it's going to cost you at least a billion-eight, taxpayers.
And now they are MOVING JOBS OUT of STATE!
"Genzyme shifting work from Allston plant; Contamination woes are cited for move; jobs won’t be affected" by Megan Woolhouse, Globe Staff | January 5, 2010
Cambridge biotechnology company Genzyme Corp. will move all its filling, packaging, and distribution operations out of its Allston drug manufacturing facility because of the latest problems involving contamination at the plant.
Genzyme officials said yesterday that they had entered into an agreement with drug maker Hospira Inc., based in Lake Forest, Ill., to take over the so-called filling and finishing process so that Genzyme will be able to replace part of its manufacturing equipment. Genzyme will also move the bulk of the operations to its own site in Waterford, Ireland. The shift in operations will not result in the loss of any jobs, the company said.
The changes come after bits of steel, rubber, and fiber were found in Genzyme’s medications, which are packaged in glass vials and distributed to doctors to be administered intravenously. The company decided to move the operations after a three-week investigation in November by the Food and Drug Administration found new contamination at the Allston site.
It was only the latest problem at the plant. Last summer, a viral contamination forced the company to ration two drugs, Cerezyme and Fabrazyme, both of which are used to treat rare genetic disorders....
Related: The Lies of Genzyme
The Needs of Genzyme Outweigh the Needs of All
An Enzymatic Insult
***********************
Last month, drug giant Pfizer Inc. said it would mount a direct challenge to Genzyme, spending up to $110 million to license the global rights to a competing treatment for Gaucher disease, an enzyme deficiency that affects about 5,700 people worldwide. It can result in bleeding, bone weakness, and enlargement of the liver and spleen.
And they aren't the only ones.
--more--"Also see: Slow Saturday Special: Genzyme Going Down
